ABM Respiratory Care pioneers intelligent, clinically advanced respiratory solutions, redefining the standard of care for individuals with compromised breathing. Committed to innovation, the company empowers patients to breathe better—both within and beyond hospital walls.
Its flagship product, the BiWaze® Cough System, replicates a natural cough to help clear airways effectively. This advanced system personalizes therapy by integrating oscillations, lung expansion therapy, and hygiene features, ensuring optimal respiratory support. Meanwhile, the Alpha Ventilator revolutionizes respiratory care with telehealth-enabled capabilities. It allows healthcare professionals to monitor and program multiple ventilators remotely in real time, reducing bedside visits and minimizing exposure to infectious diseases. Designed for both pediatric and adult patients, it seamlessly supports invasive and non-invasive ventilation across hospitals, skilled nursing facilities, and home care settings.
At Medical Fair India 2025, Vinay Joshi, Founder & CTO of ABM Respiratory Care, sat down with The Interview World for an exclusive conversation. He shared insights into groundbreaking respiratory innovations, their clinical effectiveness, and the affordability of these solutions for individual patients. He also explored global market opportunities, export potential, and how ABM’s technology enhances lung health.
Here are the key takeaways from his compelling discussion.
Q: Could you please share insights into the innovations developed by ABM Respiratory Care for treating respiratory diseases? What sets these solutions apart in terms of technology, effectiveness, and patient care?
A: ABM Respiratory Care is dedicated to lung health, developing cutting-edge solutions to keep lungs clear and functioning optimally. You’ve likely heard a lot about ventilators, especially during COVID-19, when they became a lifeline for survival. However, beyond ventilators, lung health challenges persist. Conditions like pneumonia often cause dangerous secretion buildup in the lungs, significantly increasing mortality rates. Many hospital deaths result from this issue, and countless chronic patients struggle with excessive lung secretions throughout their lives. That’s where our technology makes a difference.
We offer two groundbreaking products: BiWaze Cough and BiWaze Clear. BiWaze Cough assists elderly or physically weak individuals who cannot effectively clear their lung secretions. BiWaze Clear is an advanced, all-in-one solution that combines three therapies into a single device. It nebulizes to keep secretions moist, mobilizes them from deep within the lungs, and efficiently clears pneumonia-related blockages.
What truly sets us apart is our BiWaze platform. Unlike any other solution, it simultaneously clears lung secretions while maintaining optimal breathing. No competing product offers this dual capability. Current hospital lung-clearing procedures are slow and resource-intensive. Patients typically undergo an hour-long therapy involving nebulization, followed by manual physiotherapy. Our devices revolutionize this process—delivering the same results in just 10 minutes. Hospitals no longer need nurses moving from bed to bed for lung clearance. With our technology, every patient can receive efficient therapy in a fraction of the time.
Designed for both home and hospital use, our products seamlessly integrate into ICU settings. Even for ventilated patients battling pneumonia, BiWaze technology enables lung clearance without disconnecting from the ventilator—a game-changing innovation in respiratory care.
Q: As these products are designed for individual use, how affordable are they for consumers? What measures has ABM Respiratory Care taken to ensure accessibility and cost-effectiveness?
A: These are high-end medical devices, and in countries like the U.S. and Europe, insurance typically covers their cost. Reimbursement systems ensure patients can access them without financial strain.
In India, however, we recognize the need for a different approach. Rather than relying on upfront purchases, we propose a rental model, making these devices more accessible and affordable. This system not only reduces financial barriers but also maximizes efficiency. Designed with strict hygiene standards, our products can be safely used across multiple patients, ensuring both affordability and widespread availability.
Q: What are the daily rental charges for the product, and do they vary based on the duration of use?
A: The final cost ultimately depends on the provider. As manufacturers, we focus on delivering the technology, while providers handle additional expenses such as transportation, home installation, and maintenance. However, the products themselves are priced in the range of three to four lakh rupees.
Q: Are you exporting these products internationally, or is your focus primarily on the Indian market?
A: Currently, we primarily export our products, with the majority reaching the U.S. and Europe. This marks our first effort to explore the Indian market and assess its potential for these advanced respiratory care solutions.
Q: What are your insights on the market opportunities for these products in India, and how do you see the demand evolving?
A: Awareness is the first challenge. Countless patients live with these conditions, yet many remain unaware of advanced solutions. We believe medical universities and colleges should play a key role in bridging this gap.
Currently, most interest comes from doctors returning from the U.S., where these products are well-known. They recognize their value and advocate for them in hospitals. However, widespread adoption in India requires a broader awareness campaign, starting with medical education.
Q: How many devices does ABM Respiratory Care manufacture annually?
A: We manufacture approximately 20,000 to 25,000 units annually. However, our market penetration remains under 10%, highlighting the vast untapped potential.
Q: Could you elaborate on how this technology functions to clear the lungs and improve respiratory health?
A: Lung secretions, or mucus, have a thick, gel-like consistency, making them difficult to clear. However, when exposed to high-frequency oscillations, they become more fluid and easier to mobilize. Our technology achieves this through a two-step process. First, it delivers rapid, high-frequency oscillations that break down mucus viscosity. Second, it uses a unique airflow mechanism—pushing air in at a slightly lower speed than it pulls air out. This controlled push-and-pull action, performed at high frequency, effectively moves secretions upward, facilitating clearance and improving respiratory function.
